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ABSTRACT
Octreotide acetate (octreotide) is the most prescribed and
most studied somatostatin congener, or analog, for gastro-
enteropancreatic neuroendocrine tumors (GEP-NETs) and
carcinoid syndrome, the latter of which may be character-
ized by debilitating diarrhea and flushing. Approved in the
U.S. more than 30 years ago, octreotide is widely used to
control the symptoms of carcinoid syndrome and has been
shown to demonstrate antiproliferative activity. The two
formulations available in the U.S. include a subcutaneous
immediate-release (IR) injection introduced in 1989 and a
long-acting repeatable (LAR) intramuscular injection
approved in 1999. Lanreotide depot (lanreotide), a more
recent somatostatin congener, has been available in the U.S.
since 2014.
Despite widespread use of octreotide LAR, several key
challenges exist with the current depot-based treatment
paradigm. Studies indicate that LAR formulations are associ-
ated with continued unmet patient needs, owing in part to
a loss of bioactivity over time that may necessitate progres-
sive supplemental treatment with IR octreotide to ade-
quately control symptoms. Clinicians should understand the
key differences in the pharmacokinetic profiles of the LAR
and IR formulations that may contribute to bioactivity loss
and somatostatin receptor desensitization. In addition,
there is a need to re-evaluate the role of IR octreotide in
combination with depot therapy to provide consistent bio-
availability and better control of carcinoid syndrome
symptoms.
The purpose of this review is to explore all these issues
and to re-establish a rationale for the IR formulation, partic-
ularly with respect to novel use cases and its use during the
COVID-19 pandemic. The Oncologist 2021;26:e1171–e1178
Implications for Practice: There is a need to re-evaluate the role of immediate-release octreotide in combination with
depot therapy to provide consistent bioavailability and better control of carcinoid syndrome symptoms.
NEUROENDOCRINE TUMORS AND CARCINOID SYNDROME
Pathophysiology and Symptomatology
Neuroendocrine tumors (NETs) of the widely diffused neu-
roendocrine cell system frequently present substantial diag-
nostic and therapeutic challenges. Well-differentiated NETs,
traditionally known as carcinoid tumors, are the most com-
mon type of NET, with an estimated incidence of more than
12,000 U.S. cases annually (6.98 per 100,000 persons in
2012) [1]. The prevalence of NETs is estimated at 175,000
people in the U.S. NETs of gastrointestinal (GI) origin
include the appendix and ileum (the most common), the
respiratory tract, the genitourinary system, and several
organs [2]. Both incidence and prevalence of NETs are ris-
ing, and NETs are anticipated to emerge from rare disease
status within the next decade [1].
Patients with advanced, functional NETs may experience
symptoms related to tumoral secretion of serotonin and peptide
hormones, such as gastrin, glucagon, insulin, vasoactive intestinal
peptide, and, rarely, somatostatin, parathyroid hormone-related
protein, adrenocorticotrophic hormone, growth hormone, and
thyroid-stimulating hormone [2]. Most of these tumors are
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malignant and predominantly associated with increased plasma
serotonin levels, which drive symptoms in small-bowel tumors
[2]. These augmented serotonin levels, as well as increased activ-
ity from other potential substances such as histamine, kallikrein,
prostaglandins, and tachykinins, may mediate a serious condition
called carcinoid syndrome (CS), which manifests as episodic facial
flushing; urgent, debilitating diarrhea; and potential development
of fatal cardiac valvular fibrosis and mesenteric fibrosis [3, 4]. Car-
cinoid syndrome is estimated to occur in 30%–40% of patients
with well-differentiated GI NETs [5].
Diarrhea secondary to CS occurs in 58%–100% of
patients [5]. It tends to be watery after the first or second
bowel movement; movement frequency can range from
two per day to more than 20 per day [6]. Diarrhea is a mul-
tifaceted symptom, driven by stool form, consistency, fre-
quency, and urgency [7], and it can be extremely
debilitating, often requiring fluid and electrolyte manage-
ment [6]. It affects quality of life (QoL) and mental health
status and often results in significant changes to patient
lifestyle, including diet, work, physical activity, and social
life [5]. Patients with CS-induced diarrhea also experience
economic challenges [8, 9]. One study found that the mean
annual cost to patients with malignant GI NETs was nearly
double that of the national average for all cancers
(>$70,000 vs. $38,000) [10]. Diarrhea is the primary rea-
son patients seek medical help, which makes effective long-
term treatment for this NET condition essential [11]. Early
identification and management of symptoms is critical to
reducing both disease burden and cost.
Differential Diagnosis
NETs are diagnosed through histological verification of
hematoxylin eosin-stained tissue and the presence of the
neuroendocrine markers synaptophysin and/or chromo-
granin A. Neuroendocrine neoplasms are graded according
to Ki-67 index and mitotic count. They are clinically classi-
fied by both site of origin and hormonal secretion [12]. The
use of 68Ga (gallium) and 64Cu (copper) linked to somato-
statin analogs and localized with positron emission tomog-
raphy/computed tomography imaging is increasing and can
lead to more accurate tumor staging and preoperative
imaging (sensitivity 91%, specificity 94%) [13, 14]. Neuroen-
docrine neoplasms are typically considered either early
(completely resectable) or advanced (unresectable/meta-
static) [12].
Impact of Symptoms on Patient QoL
NETs and symptoms associated with CS significantly erode
patient QoL. Higher frequency of bowel movements, diar-
rhea, urgency, fecal incontinence, and cutaneous flushing
correlate with decreased QoL, which in turn affects patient
work, diet, social life, and physical activity [6, 15].
One survey examined the effect of NET treatment on
patient QoL. Patients with recurrent disease reported
poorer physical, social, and mental function compared with
controls having no current NET. Depression scores between
groups were similar; however, patients with recurrent dis-
ease reported significantly greater anxiety. The difference in
physical functioning between groups was even more strik-
ing; patients with recurrent NETs reported notably more
fatigue and impaired overall physical function and sleep
quality than those with no current NETs [16].
THE ROLE OF SOMATOSTATIN ANALOGS IN TREATING NETS
Guidelines and the Role of Somatostatin Analogs in
the Current Treatment Paradigm
Neuroendocrine tumors are highly heterogeneous, and all
elements must be considered (e.g., disease burden, symp-
toms, histopathology, rate of growth) to determine the best
course of treatment [13]. Obtaining relief from diarrhea
and flushing and achieving biochemical control are funda-
mental aspects of improving QoL in patients with symptoms
of functioning NETs. Because the disease course is often
long, symptom management and palliative care are particu-
larly important to preserving QoL [11].
Both the National Cancer Comprehensive Network
(NCCN) and European Society for Medical Oncology (ESMO)
guidelines recommend surgery as first-line treatment of
NETs [13, 17]. However, more than 80% of patients present
with advanced, nonresectable disease [11]. In addition, con-
servative management is often recommended for elderly
patients or those with significant comorbidities and lesions
≤2 cm [17, 18]. Beyond surgical intervention, the somato-
statin congeners (more commonly known as analogs)
octreotide acetate and lanreotide have had the most pro-
found effect on NET management [13, 19].
Somatostatin analogs (SSAs) are standard first-line ther-
apies for functional NETs, according to the NCCN, ESMO,
and North American Neuroendocrine Tumor Society
(NANETS), and they are generally used to control tumor
growth and associated clinical symptoms [13, 17, 20]. Posi-
tive somatostatin receptor status is generally required but
is not necessarily predictive of response, owing in part to
its tendency to miss lesions <1 cm in size. Per NCCN guide-
lines, SSAs are also indicated in patients with hormonal
symptoms [13]. In patients with uncontrolled symptoms,
ESMO recommends reducing the injection interval of long-
acting SSAs to every 2 or 3 weeks (instead of every
4 weeks) or adding short-acting octreotide. It is worth not-
ing that, despite its addition to the guidelines and common
application in clinical practice, increased injection frequency
is off label for both octreotide and lanreotide products [17].
Use of SSAs to Manage the Symptoms of CS
In addition to controlling diarrhea and flushing, SSAs are
also used to manage other aspects of CS, such as carcinoid
heart disease and mesenteric fibrosis [9]. Vasoactive sub-
stances produced by NET tumors can induce myofibroblast
proliferation and deposition of extracellular matrix within
the heart, and local desmoplastic response around the
tumor [6, 9]. Results of SSAs, although mechanistically
promising, have been mixed. This may be because SSAs only
reduce, not eliminate, circulating levels of bioactive sub-
stances responsible for fibrosis. More conclusive work is
needed to discern the true impact of SSAs on these
responses [9].
© 2021 The Authors.
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Historical Perspective of Somatostatin Analogs and
the Evolution of the LAR-Based Treatment Paradigm
The discovery of somatostatin in 1973 provided a new
approach to treating diseases such as NETs and acromegaly
that are associated with endocrine hypersecretion [21]. In
1989, the U.S. Food and Drug Administration (FDA) approved
octreotide acetate subcutaneous (SQ) immediate-release
(IR) injection for the treatment of CS and the diarrhea of vaso-
active intestinal peptide carcinoma syndrome [19].
In a 1999 study, approval of the LAR intramuscular
(IM) formulations (10, 20, and 30 mg once monthly) contin-
ued to expand the clinical application of octreotide [22].
The LAR formulation is administered intramuscularly once
every 28 days [23]. In 2014, the FDA approved somatuline
depot (lanreotide acetate) SQ injection monthly for
improvement of progression-free survival in patients with
GEP-NETs. Subsequently, in 2017, lanreotide was also
approved for treatment of CS to reduce the frequency of
short-acting somatostatin analog rescue therapy [24, 25].
A study by Modlin et al. of pooled data from more than
14 trials spanning 20 years (n = 400 patients) revealed
that 71% of patients with GEP-NETs experienced resolution
or improvement of diarrhea (range, 40%–88%) and flushing
(range, 485–100%) after treatment with octreotide [26].
Clinical trials also support a reduction in the number of days
patients on lanreotide experience diarrhea and/or flushing
[27]. However, recent data from a large observational
cohort shows that 43% of study subjects still experienced
diarrhea after 6 months of lanreotide therapy compared
with 44% at baseline [28].
The most common adverse effects associated with SSAs
include nausea, abdominal cramps, loose stools, mild steat-
orrhea (because of meal-stimulated inhibition of pancreatic
exocrine secretion and subclinical fat malabsorption), and
flatulence. Subclinical fat malabsorption may be exacer-
bated in the setting of higher fat consumption with daily
meals. These symptoms start within hours of the first SQ
injection, are dose dependent, and usually spontaneously
subside within the first few weeks of treatment. All SSA for-
mulations are well tolerated by most patients [29].
Although octreotide and lanreotide have similar indica-
tions, their pharmacokinetics (PK) profiles are dissimilar.
Octreotide LAR has a more predictable PK profile than pro-
longed release lanreotide. The steady-state PK of lanreotide
is higher than that of octreotide, which can potentially
increase the risk of dose-dependent side effects. However,
the lanreotide 120-mg profile has been found to be compa-
rable with the 90-mg profile, which suggests that lanreotide
is not strictly dose proportional. The high variability in mean
maximum concentration (Cmax) and lack of dose propor-
tionality with lanreotide suggest that uptitrating from
90 mg to 120 mg may not produce a predictable effect or
improve efficacy in every patient [23].
Owing to a lack of randomized trials, no data to guide
sequencing of the systemic therapy options are currently
available [20]. In a recent retrospective administration
claims analysis of almost 3,000 patients with NETs, >80%
were prescribed octreotide LAR, in part because of its dos-
ing convenience over the IR formulation [18, 29, 30].
Current Use Cases for Octreotide IR
The IR formulation is rarely used alone for long-term ther-
apy but can be particularly effective as rescue therapy in CS
patients [11]. Unlike the LAR formulation, which is designed
to release the drug over a 28-day period [30], the IR formu-
lation has a short half-life (1.7–1.9 hours) and is immedi-
ately bioavailable, permitting administration up to three
times a day [31]. Supplemental IR octreotide is required for
approximately 2 weeks after octreotide LAR treatment is
initiated or until steady-state is achieved. Intermittent res-
cue IR injections may also be required for rapid relief of
acute or breakthrough symptoms [13, 31].
In a single study, 30%–40% of patients receiving
monthly somatostatin therapy required octreotide rescue
medication at 4 weeks to fully control CS symptoms [22].
However, analysis of an administrative claims database
showed that only 2% of patients prescribed octreotide filed
coverage claims for both LAR and IR formulations [18].
Despite the potential benefits of octreotide IR as rescue
therapy, it remains underutilized.
CURRENT OCTREOTIDE LAR-BASED TREATMENT PARADIGM:
CHALLENGES AND OPPORTUNITIES FOR CLINICAL
IMPROVEMENT
Areas of Unmet Clinical Need
Despite the breadth of evidence and advances in NET treat-
ment, studies have shown that most of these patients live
with significant physical challenges and unmet needs [32].
For instance, ongoing diarrhea is common and most often
due to incompletely controlled CS [6]. In a large, interna-
tional, online survey, 741 with NETs reported fatigue
(66%), diarrhea (48%), sleep disturbance (35%), and
pain and discomfort (40%) as their greatest physical chal-
lenges (Fig. 1) [32].
In an online survey of 100 patients with NETs who were
currently on SSA therapy, the most frequently reported CS
symptoms were diarrhea (90%), flushing (78%), and weight
gain/loss (48%). Twenty-nine percent of patients reported
daily diarrhea, and 23% experienced daily flushing episodes.
Sixty-five percent of patients reported having to stop physi-
cal activities, whereas 57% reported difficulty sleeping due
to NETs symptoms. Most concerning were the levels of anx-
iety and depression in patients with NETs, with results
showing that 45% of patients were affected and may have
needed to seek mental health treatment [33]. These studies
indicate that most patients are coping with their disease
but need better management of other coassociated symp-
toms [32].
Receptor Desensitization and Tachyphylaxis
With widespread adoption of the octreotide LAR formula-
tion, clinicians have observed that eventual resistance
and tachyphylaxis to octreotide LAR is common, if not
inevitable. During long-term therapy, a gradual reduction
in sensitivity to octreotide with regard to its clinical
effect and inhibitory action on hormone secretion has
been reported [34].
© 2021 The Authors.
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In a study evaluating long-term results of lanreotide
depot treatment in malignant CS, 46% of patients experi-
enced loss of symptomatic response and radiologic
response at a median 42 months (range, 8–107). Forty-four
percent achieved control after a dose increase to
120 mg/28 days. However, 56% of the patients who lost
response required additional treatment [35].
Somatostatin receptor 2 (SSTR2) desensitization and
lower suppression despite octreotide and lanreotide treat-
ment, particularly in GEP-NETs, has been an important clini-
cal observation [36]. In an open-label, randomized,
multicenter study designed to assess two dose levels of
octreotide LAR, 124 patients with active or prior
chemotherapy-induced diarrhea and scheduled chemother-
apy were randomized to receive up to six doses of either
octreotide LAR 30 or 40 mg (above-label dose). Both dose
levels provided clinical benefit, although fewer patients in
the 40-mg group than the 30-mg group experienced severe
diarrhea (48.4% vs. 61.7%, p = .14), required intravenous
(IV) fluid (18.8% vs. 31.7%, p = .10), and had diarrhea-
related unscheduled health care visits (28.1% vs. 41.7%,
p = .11). However, no significant differences in QoL or treat-
ment satisfaction were observed between the treatment
groups. These results suggest that patients, irrespective of
dose, may need rescue therapy with octreotide IR to mitigate
receptor desensitization [37].
Attempting Improved Control Through Dose
Escalation
The FDA label recommends a starting dose of 20 mg of
octreotide LAR, with titration up to 30 mg in patients with
suboptimally controlled symptoms [31]. However, in current
clinical practice, above-label doses of octreotide LAR are
commonly prescribed for patients with metastatic NETs
who show suboptimal control of CS or tumor growth while
on the maximum label dose of octreotide LAR [38].
Studies have suggested that an above-standard dose of
octreotide LAR may improve symptom control among
patients who have CS symptoms prior to dose escalation
[39]. In current clinical practice, 13%–30% of patients
receive above-standard LAR doses in an effort to ade-
quately control symptoms or suppress tumor progression
[18, 40]. Similar responses to dose escalation are often dis-
cussed with lanreotide therapy in cases of symptomatic and
radiologic progression [35].
Often the circulating octreotide drug levels produced by
LAR doses 10, 20, or 30 mg/month do not completely satu-
rate SSTR2 receptors in all patients [41]. Chronically under-
saturated receptors combined with desensitization
mechanisms can increase production of somatostatin recep-
tors, creating an escalating cycle [41].
Higher doses of octreotide LAR comes at increased cost.
According to recent estimates, the additional annual costs
for above-label dosing range from $5,000 to $40,000 per
patient, depending on the amount of octreotide they are
given [18]. These costs may be mitigated, and symptom
control improved, in part by choosing the appropriate IR
formulation to supplement vs increasing the dose.
Limited Bioavailability of LAR Formulations
The octreotide LAR formulation is available in a vial con-
taining the sterile drug product, which, when mixed with
the diluent, becomes a suspension administered as a
monthly intragluteal injection. Intramuscular injection is not
typically 100% bioavailable as it must be absorbed from the
muscle over time [42]. Label-reported bioavailability for
the LAR formulation is only 60–63%, with a large portion of
the drug excreted [30].
Variability in operator skill and experience administering
the IM octreotide injection can sometimes pose a chal-
lenge. A study of 115 patients evaluated the outcomes of
328 intended gluteal octreotide IM injections. Only 52%
of injections were successfully delivered at baseline [43].
Most patients receive LAR as IM injections in the upper
outer quadrants of the buttocks. Repeated injections at




















































France (n = 60) Germany (n = 222) US (n = 374)
Figure 1. Physical challenges of living with NETs. Proportions of respondents who experienced each challenge in France, Germany,
and the US are shown. *Other symptoms include pain, vomiting, and shortness of breath. †No German patients specifically selected
“diarrhea,” but 20% of those who selected “other” stated that they had diarrhea after an operation. It is unknown whether they
experienced diarrhea beforehand. Diarrhea could be caused by consequences of surgery and treatments rather than the disease.
Data source: Khan et al [32].
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effectiveness, owing to a well-described association
between these injections and granulomatous reactions in
the gluteal muscle [41].
Another potential factor contributing to decreasing effi-
cacy of the LAR formulation is an unanticipated change in
the drug formulation. A change in the size, distribution, or
thickness of the microsphere’s polymer coating could signif-
icantly alter the drug-release characteristics of the LAR
preparations [41].
RATIONALE FOR USE OF OCTREOTIDE IR IN CURRENT
CLINICAL PRACTICE
Increased Absorption and Bioavailability of IR
Formulations
Octreotide is rapidly and completely absorbed after SQ
injection. Peak concentrations of 5.2 ng/mL (for a 100-μg
dose) were reached 0.4 hours after dosing (Table 1). Using
a specific radioimmunoassay, both the IV and SQ doses
were deemed to be bioequivalent. Peak concentrations and
area under the curve values were dose proportional after IV
single doses up to 200 μg, SQ single doses up to 500 μg,
and after SQ multiple doses up to 500 μg three times daily
(1,500 μg/day) [30].
As expected, the PK of the octreotide IR formulation dif-
fer from that of the LAR formulation. These dissimilarities
affect blood level concentrations and the medication’s clini-
cal effect. When the IR formulation is administered SQ, and
absorption is 100%, thus making the drug 100% bioavailable
[31, 41]. Because the drug’s onset of action is faster, CS
symptom relief is quicker.
Octreotide binds with a high affinity to SSTR2 and SSTR5
[44]. For effective pharmacologic activation and symptom
control, nearly complete saturation of SSTR2 should occur,
with circulating drug levels 10 times higher than the dis-
sociation constant (Kd). The binding affinity (Kd, 50% recep-
tor saturation) of octreotide to SSTR2 is 1 nM (1,000
pg/mL), meaning that octreotide levels within the blood-
stream should be 10,000 pg/mL. Studies have demon-
strated that the 10,000-pg/mL level can be achieved only
with the IR formulation of octreotide [41].
Octreotide IR Mimics Natural Somatostatin
The pharmacodynamic properties of octreotide IR are like
those of somatostatin, with a wide spectrum of inhibitory
effects on pituitary, GI, and pancreatic functions, as well as
gut endocrine secretions. Compared with native somato-
statin, octreotide is highly resistant to enzymatic degrada-
tion and has a prolonged plasma half-life of 100 minutes
in humans, allowing its use in the long-term treatment of
various disease states [45]. The octreotide IR formulation
delivers a predictable peak, plateau, and half-life, and it
mimics the natural levels of somatostatin in the body, which
is a significant difference and advantage over the LAR
formulation.
Novel Use Cases for IR Octreotide
Treatment of Breakthrough Symptoms
Patients taking monthly injections of octreotide LAR may
experience breakthrough symptoms triggered by certain cir-
cumstances. For example, with long-term octreotide LAR or
lanreotide depot therapy, vitamin D absorption becomes
compromised as a result of prandial inhibition of pancreatic
enzyme release. Vitamin D25 levels will subsequently
decrease and remain low, potentially exposing the patient
to a long list of symptoms. For such patients, a trial of res-
cue octreotide IR taken 30 minutes prior to meals may slow
serotonin-induced fat malabsorptive diarrhea. In fact, taking
octreotide 30 minutes before a meal along with pancreatic
enzymes and a vitamin D supplement at least once daily
may slowly improve vitamin D25 blood levels [19].
Octreotide IR is effective in symptomatic carcinoid
patients anytime serotonin levels rise. Physical exercise or
exertion, alcohol consumption, or physical or emotional
stress can cause these levels to rise dramatically. Prophylac-
tic or on-demand use of IR therapy can prevent the seroto-
nin surges induced by these events. Medical or dental
procedures, as well as intercurrent illnesses may also exac-
erbate symptoms despite octreotide LAR therapy. Treating
these “breakthrough” symptoms with 100–500 μg of
octreotide IR SQ every 6 to 12 hours has been shown to
provide effective symptom control [19].
Preoperative preparation with SSAs to prevent
intraoperative carcinoid crisis has been suggested, primarily
for patients with known or high risk of CS. However, it is
not currently known what molecules mediate intraoperative
crisis. A prospective assessment of biochemical and hemo-
dynamic features of intraoperative crisis failed to identify a
rise in serotonin. Outcomes following intraoperative carci-
noid crisis were related to prompt identification and man-
agement of hemodynamic instability rather than the
preoperative preparation [17, 20].
In patients treated with SSAs but experiencing refrac-
tory diarrhea, addition of telotristat ethyl can be consid-
ered, as it reduces bowel movement frequency. If diarrhea
remains uncontrolled, additional treatment options, like
narcotics, steroids, or surgical dissection, may be explored.
For flushing not adequately controlled by SSAs, tumor
debulking or chemoembolization represent viable treat-
ment options [6].
Use as a Supplement to Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT) with 177Lu-
dotatate is often considered to improve symptom control in
patients with progressive disease and well-differentiated
Table 1. Comparative pharmacokinetics of octreotide LAR
and IR
Pharmacokinetic characteristic LAR, % IR, %
Bioavailability 25–30 100
Peak-to-trough variation 44–68a 163–209a
From refs. [31, 41].
aWhen octreotide LAR was administered intramuscular every
4 weeks, the peak-to-trough variation in octreotide concentrations
ranged from 44% to 68% compared with the 163% to 209% varia-
tion encountered with the subcutaneous 3 times daily regimen of
octreotide injection solution [30].
Abbreviations: IR, immediate-release; LAR, long-acting repeatable.
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NETs who have detectable SSR expression and adequate
bone marrow, renal, and hepatic function [13, 17]. PRRT
efficacy may not be durable, however, and it is often
followed by additional SSA therapy, as full resolution of CS-
related symptoms is rarely achieved [17].
There are theoretical concerns regarding competition
between SSAs and PRRT treatment for SSR binding [13]. There-
fore, guidelines suggest that long-acting SSAs be interrupted at
least 4 weeks before PRRT [17]. Short-acting octreotide can be
administered as needed for symptom control up to 24 hours
before PRRT administrations. Additionally, when octreotide is
used around a cycle of PRRT, it should be given immediately
after completion of the cycle to avoid binding competition [13].
Small-Bowel Obstruction
Small-bowel obstruction interferes with food intake and can
cause nausea and diarrhea in patients with nonoperable termi-
nal cancer. Palliative care is often paramount to these patients,
but antiemetics, steroids, and anticholinergics are often insuffi-
cient to control symptoms [46]. Octreotide IR has been shown
to help control vomiting, one of the most distressing symptoms
experienced by some terminal patients [47].
Clinical trial results for the use of octreotide IR in
patients with small-bowel obstruction have been mixed. Early
data and open-label, single-arm studies show overwhelming
evidence for the benefits of octreotide, especially in patients
with gynecologic and urologic cancers [48]. In initial small-
scale studies using a continuous infusion of 300 μg/day,
vomiting was generally controlled rapidly, with 92.8% patients
achieving at least a partial response and 71.4% able to resume
oral food intake [49]. However, placebo-controlled studies
often find similar improvements in both frequency of symp-
toms and QoL outcomes between octreotide and placebo-
controlled groups [48, 50]. Despite these mixed results, some
societal guidelines, like ESMO, recommend administering
octreotide IR, either subcutaneously or via continuous infu-
sion, to treat refractory symptoms [51].
Carcinoid Crisis
Carcinoid crisis is a serious and potentially life-threatening
condition, caused by the release of large amounts of 5-HT and
other vasoactive peptides into circulation. Characterized by
hypotension, arrhythmias, and tachycardia, carcinoid crisis can
occur spontaneously but can also be triggered by surgery or
stress. To prevent carcinoid crisis that could be induced by
these latter circumstances, patients often use octreotide IR
prophylactically [15]. The ideal administration schedule for
octreotide IR to prevent carcinoid crisis remains unknown, but
guidelines (ENETS, NANETS, and UKNETS) suggest different
octreotide dosing schedules, including pre-, intra-, and/or
postoperative, to prevent symptoms [52].
OCTREOTIDE IR USE DURING COVID-19
The COVID-19 pandemic has posed challenges for many
patients, including those with NETs. Treatment of NETs is a
health resource-heavy process. In prepandemic studies,
patients with NETs averaged 25.7 outpatient visits and 5.6
inpatient visits annually, with the most common being visits
to oncologist offices [18, 53].
In response to governmental regulations and individual
health concerns, oncology patient visits dropped dramati-
cally in 2020 and, despite the lifting of stay-at-home orders,
oncology service use continues to lag behind 2019 levels
[54]. In an observational multicenter study, up to 40% of
patients interrupted their therapy over the past year, in part
because of the pandemic’s impact on in-office visits [55].
An initial report from the Italian Association for Neuro-
endocrine Tumors reported a significant impact of the
COVID-19 pandemic on the number of newly diagnosed
cases of NETs, as well as a reduction in surgical procedures
and delays in beginning scheduled PRRT.
Although many providers have been able to switch to tele-
medicine during the pandemic, remote visits preclude admin-
istration of octreotide LAR. At-home injections of octreotide
IR, combined with telemedicine, can offer patients viable and
effective symptom relief and provide clinicians with the oppor-
tunity to treat and monitor their patients while also reducing
the exposure of both to COVID-19 [56].
CONCLUSION
Once octreotide steady-state concentrations are achieved,
octreotide LAR controls the symptoms of CS at least as well
as octreotide IR [22]. However, driven mainly by its PK pro-
file, the IR formulation shows unique advantages in a range
of patients who can benefit from the better symptom con-
trol not provided by the LAR formulation alone. Supplemen-
tal use of octreotide IR is consistent with current and
emerging NETs clinical practice guidelines [13, 17, 20]. Sim-
ulated steady-state profiles suggest that LAR octreotide
therapy could be optimized by using octreotide IR to meet
individual patient needs, thereby improving both patient
experience and clinical outcomes [23].
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